Modafinil
Also known as: Provigil, Modalert, Modvigil, Armodafinil, Nuvigil
Eugeroic | Wakefulness & Cognitive Enhancement
Overview
Modafinil is a wakefulness-promoting agent (eugeroic) originally developed in France in the late 1970s and approved by the FDA in 1998. It is prescribed for the treatment of excessive daytime sleepiness associated with narcolepsy, shift work sleep disorder, and obstructive sleep apnea. Unlike traditional psychostimulants such as amphetamines, modafinil produces wakefulness and alertness with a markedly lower abuse potential and a more favorable side effect profile. It has become one of the most widely used compounds in the nootropic and biohacker community due to its ability to sustain focus, reduce fatigue, and enhance executive function during extended periods of cognitive demand. Armodafinil, the R-enantiomer, is marketed separately under the brand name Nuvigil and offers a longer duration of action at a lower dose.
Key benefits
- Sustained wakefulness and alertness for 10-15 hours without the jitteriness of traditional stimulants
- Enhanced executive function, working memory, and decision-making under fatigue
- Improved focus and concentration during prolonged cognitive tasks
- Reduced impulsivity and improved task completion in sleep-deprived individuals
- Low abuse potential relative to amphetamine-class stimulants (Schedule IV)
- Minimal impact on normal sleep architecture when taken in the morning
Mechanism of action
The exact mechanism of action of modafinil is not fully understood, which distinguishes it from most prescription stimulants. The primary mechanism appears to involve inhibition of the dopamine transporter (DAT), leading to increased extracellular dopamine concentrations in the nucleus accumbens and cortical regions. However, modafinil's pharmacological profile is distinct from classical dopaminergic stimulants. It also modulates several other neurotransmitter systems: it increases histamine release from the tuberomammillary nucleus (promoting wakefulness), elevates norepinephrine in the prefrontal cortex and hypothalamus, increases serotonin in the amygdala and frontal cortex, and enhances orexin/hypocretin neuron activation in the lateral hypothalamus. Additionally, modafinil reduces GABA release in the cortex and sleep-promoting regions, tipping the balance toward sustained arousal. This multi-target profile is thought to explain why modafinil promotes wakefulness without the jitteriness, peripheral sympathetic activation, or crash associated with amphetamine-class stimulants.
Molecular data
- Type
- Diphenylmethylsulfinylacetamide (C15H15NO2S)
- Half-life
- ~12-15 hours
Indications
What the research community uses this compound for, with self-reported effectiveness.
Sleep Disorders
Cognitive Enhancement
Off-Label / Investigational
Dosing protocols
Common protocols by delivery method. Adjust the curve below to model accumulation in your own cycle.
Delivery method
| Protocol | Dose | Frequency | Duration |
|---|---|---|---|
| — | 200 mg | Once daily in the morning | — |
| — | 100 mg | Once daily in the morning | — |
| — | 200 mg | Once, 1 hour before shift start | — |
| — | 150 mg | Once daily in the morning | — |
Safety
Reported adverse effects, contraindications, and what to monitor on cycle.
Common side effects
- Headache (most frequently reported side effect, often dose-dependent)
- Insomnia (particularly if taken too late in the day)
- Anxiety and nervousness
- Appetite suppression and mild nausea
- Dry mouth
- Dizziness
- Gastrointestinal discomfort (diarrhea, abdominal pain)
Rare side effects
- Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) -- rare but potentially life-threatening skin reactions, more common in pediatric populations, which led the FDA to deny pediatric ADHD approval
- Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)
- Angioedema and multi-organ hypersensitivity reactions
- Psychiatric symptoms (hallucinations, mania, suicidal ideation) in predisposed individuals
- Elevated liver enzymes
- Tachycardia and palpitations
Contraindications
- Known hypersensitivity to modafinil or armodafinil
- History of Stevens-Johnson Syndrome, TEN, or DRESS with prior modafinil/armodafinil use
- Severe hepatic impairment (dose reduction required in moderate impairment)
- Unstable angina or recent myocardial infarction
- Left ventricular hypertrophy or clinically significant mitral valve prolapse with prior stimulant use
- Pregnancy (limited human data; animal studies show teratogenicity at high doses)
Monitoring
- Blood pressure and heart rate: baseline and periodically, especially in patients with hypertension
- Liver function tests: if prolonged use or signs of hepatic involvement
- Skin assessment: counsel patients to discontinue immediately at any sign of rash
- Psychiatric status: monitor for mood changes, anxiety, or psychotic symptoms, particularly in patients with psychiatric history
- Contraceptive efficacy: ensure patients using hormonal contraceptives are aware of reduced effectiveness
References
Primary literature and clinical-trial data informing this entry.